Quince Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
611 Gateway Blvd Ste 273, South San Fran...Phone Number
(415) 910-5717Website
www.quincetx.comRevenue
-Stock Symbol
QNCXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Quince Therapeutics
Quince Therapeutics is a biopharmaceutical company. It focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company was founded in 2012 and is based in San Francisco, California.Explore more
Quince Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Quince Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Quince Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Quince Therapeutics
Check if Quince Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Quince Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Quince Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Quince Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Quince Therapeutics has new funding data
Click to see if Quince Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Quince Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Quince Therapeutics
Compare insights from companies similar to Quince Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Quince Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Quince Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Quince Therapeutics.
Quince Therapeutics financials insights
Gather financial insights about Quince Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Debt
$7.6M
2025
Stock/Share Issuance
$11.5M
2026
Stock/Share Issuance
$114.7M
Quince Therapeutics Tech Stack
A closer look at the technologies used by Quince Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Person-Based
Person-Based
Person-Based
Quince Therapeutics News & Media
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET. The event will feature PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women's Hospital) and Paul Yu, MD, PhDQuince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026:Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipelineQuince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor) designed to enhance pulmonary delivery and reduce systemic exposure.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Quince Therapeutics
Sign Up For FreeTo access detailed company insights
Quince Therapeutics is a biopharmaceutical company. It focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company was founded in 2012 and is based in San Francisco, California.... Read More
